Address
Email address
Phone number
https://pharmanord.comPharma Nord - dietary supplements for your healthScientifically documented dietary supplements. Discover our well documented coq10, selenium and chromium in our webshop.
Name
Pharma Nord Eesti OÜ
Registry code
14194775
VAT number
EE101954848
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
31.01.2017 (7)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
63991 - Other information service activities n.e.c. 47911 - Retail sale via mail order houses or via Internet
700 869 €
49 531 €
7%
2 257 €
(estimate is approximate)
76 399 €
7
Submitted
No tax arrears
65%
14%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Osaühing LEINONEN 10391964 | - | Contact person | - |
| 2019 26.06.2020 | 2020 25.05.2021 | 2021 23.05.2022 | 2022 24.05.2023 | 2023 24.04.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 262 097 € | 298 566 € | 333 787 € | 509 173 € | 700 869 € |
| Net profit (loss) for the period | 13 105 € | 14 928 € | 7 033 € | 19 080 € | 49 531 € |
| Profit Margin | 5% | 5% | 2% | 4% | 7% |
| Current Assets | 72 933 € | 81 861 € | 81 173 € | 146 356 € | 359 805 € |
| Fixed Assets | 1 141 € | 8 043 € | 6 565 € | 6 117 € | 4 745 € |
| Total Assets | 74 074 € | 89 904 € | 87 738 € | 152 473 € | 364 550 € |
| Current Liabilities | 17 189 € | 18 091 € | 45 515 € | 125 605 € | 288 151 € |
| Non Current Liabilities | 16 035 € | 16 035 € | 16 035 € | 0 € | - |
| Total Liabilities | 33 224 € | 34 126 € | 61 550 € | - | - |
| Share Capital | - | - | - | - | - |
| Equity | 40 850 € | 55 778 € | 26 188 € | 26 868 € | 76 399 € |
| Employees | 5 | 5 | 5 | 5 | 7 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 293 671.74 € | 35 037.07 € | 29 698.81 € | 7 |
| 2023 Q4 | 262 454.18 € | 37 820.11 € | 30 372.56 € | 7 |
| 2023 Q3 | 146 735.4 € | 28 805.99 € | 25 798.22 € | 7 |
| 2023 Q2 | 207 370.01 € | 29 500.45 € | 26 167.12 € | 6 |
| 2023 Q1 | 199 211.55 € | 26 306.7 € | 24 109.57 € | 6 |
| 2022 Q4 | 141 174.18 € | 32 307.19 € | 23 986.03 € | 6 |
| 2022 Q3 | 195 370.69 € | 18 082.81 € | 17 316.23 € | 6 |
| 2022 Q2 | 146 300.88 € | 22 280.54 € | 20 553.4 € | 5 |
| 2022 Q1 | 95 837.63 € | 18 316.45 € | 18 163.68 € | 7 |
| 2021 Q4 | 118 532.74 € | 31 301.18 € | 21 463.47 € | 6 |
| 2021 Q3 | 103 314.67 € | 15 397.98 € | 16 042.09 € | 6 |
| 2021 Q2 | 70 491.89 € | 15 061.36 € | 15 819.74 € | 5 |
| 2021 Q1 | 76 688.81 € | 16 164.37 € | 16 669.28 € | 5 |
| 2020 Q4 | 94 328.18 € | 16 550.28 € | 15 049.78 € | 4 |
| 2020 Q3 | 58 711.19 € | 14 395.53 € | 14 464.98 € | 4 |
| 2020 Q2 | 66 850.2 € | 15 593.39 € | 16 187.83 € | 4 |
| 2020 Q1 | 75 047.02 € | 14 622.57 € | 15 090.08 € | 6 |
